Combining epigenetic drugs such as lysine-specific histone demethylase-1A inhibitors or histone deacetylase inhibitors with PARPi/anti-PD-1/PD-L1 is a novel, potentially synergistic strategy for priming tumors and overcoming resistance.
| BACKG ROU N D
Triple-negative breast cancers (TNBCs) comprise approximately 15%-20% of breast cancers and have an aggressive natural history compared to other breast cancer subtypes. 1 Triple-negative breast cancers tend to present in younger, premenopausal women and preferentially metastasize to visceral organs. 1 Despite good responses to standard cytotoxic chemotherapy regimens, recurrence is common, and retreatment with further lines of chemotherapy remains standard with suboptimal survival outcomes. Novel therapeutic drug development for TNBCs has been limited due to their heterogenous nature. There is thus an unmet need to improve therapeutic strategies for patients with TNBCs. In this review, we explore poly (ADP-ribose) polymerase inhibitor (PARPi) resistance mechanisms, hypothesize novel resistance pathways, and propose a novel combinatorial biological approach that not only overcomes PARPi resistance but also renders tumors more susceptible to immunogenic cell death and depletes the metastasis-driving cancer stem cell (CSC) population through epigenetic modulation.
Immune checkpoint inhibition and immune-mediated cytotoxicity have shown impressive durable activity in many hematological and solid organ cancers with an acceptable toxicity profile. 2 Although a large proportion of TNBCs express high levels of programmed cell death-ligand 1 (PD-L1), have a high mutational load, and are associated with high numbers of CD8 + tumor-infiltrating lymphocytes, responses to immunotherapy are not as spectacular in TNBCs compared to other cancers (Table 1) , 3 but numerous trials including multiple combinations are ongoing.
Poly (ADP-ribose) polymerase inhibitors are group of relatively novel drugs that cause cell cycle arrest and cell death by interfering with DNA repair. 4 Several PARPi have been tested in patients with various cancers including ovarian, breast, and prostate cancers.
Impressive responses have mainly been seen in early phase trials and some phase III trials, especially in BRCA-mutant ovarian cancer patients ( Table 2) . Three PARPi (olaparib, rucaparib, and niraparib) are already approved by the US FDA for the treatment of recurrent ovarian cancer and, recently, olaparib also received approval for the treatment of BRCA-mutant human epidermal growth factor receptor 2-negative metastatic breast cancer. Despite promising early data, resistance develops in most patients with no significant improvement in overall survival (OS).
5,6

| P OLY ( ADP -RIBOS E) P OLYMER A S E AND PARPI
The role of PARP1 in DNA damage responses is diverse and has been extensively studied ( Figure S1 ). Poly (ADP-ribose) polymerase 1 activity is triggered by binding of PARP1 to single-strand breaks through the two zinc fingers at the N-terminal 42 kDa DNA-binding domain, which leads to enzymatic activation. 7 Using NAD as a substrate, PARP1
catalyzes the transfer of polymer of ADP ribose (PAR) molecules to glutamate, lysine, or aspartate residues on acceptor histone and/or non-histone proteins, thereby mediating the recruitment of DNA repair proteins and eventually DNA repair. AutoPARylation of PARP1 eventually enables dissociation of PARP1 from DNA to complete DNA repair. 7 The effects of PARPi on DNA damage and the cell cycle are complex. Most PARPi are competitive NAD + inhibitors that are cytotoxic by inhibiting PARylation and by trapping PARP1 on DNA, which blocks the progression of replication forks, eventually leading to cell death. 8 In contrast, a recent report suggested that PARPi might increase the speed of fork elongation (rather than stalling it) beyond a tolerable threshold, eventually leading to cell death. 9 Synthetic lethality is a concept in which defects in one or two genes/repair mechanisms have minimal effects on the cell, whereas defects in combinations of genes/repair mechanisms are lethal. 14-16
TA B L E 1 Immunotherapy in breast cancer
| P OLY ( ADP -RIBOS E) P OLYMER A S E INHIB ITOR S IN B RE A S T C AN CER
| RE S IS TAN CE TO PARPI
Poly (ADP-ribose) polymerase inhibitor-treated cells acquire resistance either directly or indirectly related to restoration of HR repair or through other mechanisms. These can be broadly categorized into 7 groups (Table 3) ; secondary mutations that overcome the BRCA1 pathway deficiency are the best-studied mechanism of PARP resistance. Other known resistance mechanisms include partial or complete restoration of HR repair through rewiring of DNA damage response, either through loss of 53BP1 and Shieldin complex proteins that restrain DNA end resection, 17 or through regulation of HR genes. 18 More recently, SFLN11 has emerged as a promising biomarker of PARPi sensitivity. SFLN11 facilitates DNA replication arrest and cell death, hence potentiating the "trapping" effect of PARPi, 19, 20 and SLFN11 inactivation confers resistance to PARPi in many cancer cell lines. 21 
| OVERCOMING RE S IS TAN CE BY COMB INATION APPROACHE S
Poly (ADP-ribose) polymerase inhibitor combinations tested thus far have been based on 3 biological interactions. Cb, carboplatin; chemo, chemotherapy; HR/P, hazard ratio/P value; NA, not applicable; NR, not reported; ORR, overall response rate; OS, overall survival; P, paclitaxel; PFS, progression-free survival; Pl, placebo; Tem, temozolomide; V, veliparib.
TA B L E 2 Poly (ADP-ribose) polymerase inhibitor trials in breast cancer
| Increasing DNA damage
Poly (ADP-ribose) polymerase inhibitors have been shown to increase the DNA damage caused by cytotoxic chemotherapy or by interrupting DNA repair pathways. This approach was limited by toxicity, predominantly myelosuppression, despite various dose and scheduling modifications. 12, 22 In addition, many DNA repair pathways are upregulated to compensate for PARPi (eg CHK1/2, CDK1, Wee1, and MET1), and interfering with these can augment PARPi efficacy. 22 
| Increasing PARP trapping
Poly (ADP-ribose) polymerase inhibitors differ in their ability to trap PARP1 on DNA. Cytotoxicity was greater with olaparib/temozolomide than veliparib/temozolomide, which was attributed to the greater trapping ability of olaparib compared to veliparib. However, synergy between topoisomerase 1 inhibitors and PARPi was more dependent on catalytic activity rather than trapping. 22 Hence, appropriate selection of combinations based on PARPi biology is important to achieve synergy.
| Simulating BRCAness in
BRCA-proficient tumors
Some tumors inherently express BRCAness despite being BRCA proficient and could be sensitive to PARPi. In others, silencing BRCA expression or depleting proteins involved in BRCA-associated HR creates BRCAness and increases PARPi sensitivity. 23 McCabe et al 24 reported
that defects in other DNA repair genes commonly found in human cancers including those involved in DSB detection and repair rendered tumors susceptible to PARPi. Recently, inhibition of BET genes (in particular BRD4) or related proteins has been shown to sensitize cancers to PARPi by inducing BRCAness through downregulation of CTIP, BRCA1, and RAD51 transcription. 25, 26 Deficiencies in several other pathways could also increase PARPi sensitivity, and drugs inhibiting the mTOR/PI3K pathway, heat shock protein 90 (HSP90), and histone deacetylase inhibitors (HDACi) are currently undergoing trials. 
| NOVEL THEORIE S OF PARPI
27
The combination of PARPi and immunotherapy is one novel approach currently being investigated (Table S1 ). found that, although combined CTLA4 and PARP1 inhibition was synergistic, combining a PD-L1/PD1i with a PARP1i had no effect.
However, these studies have notable differences: the former used only breast cancer cell lines including MDA-MB-231, SUM149, and Other Upregulation of NF-κB signaling 84 CSC, cancer stem cell; EZH2, enhancer of zeste homolog 2; HOXa9, homeobox A9; HR, homologous recombinant; NF-κB, nuclear factor-κB; SLFN11, Schlafen family member 11. 
| Cancer stem cell theory
Cancer stem cells are a small subpopulation of cancer cells found in the tumor mass that express unique cell surface marker profiles like CD44 high /CD24 low , and epithelial cell adhesion molecule (EPCAM) in breast cancer, and CD133 in colon, brain, and lung cancers. 33 There is increasing evidence that they play crucial roles in tumorigenesis, invasion, and metastasis. 33 Cancer stem cells are inherently more resistant to standard chemotherapy and radiotherapy, so are implicated in the development of tumor progression, resistance, metastasis. 34 Many features of CSCs confer the drug-resistant phenotype:
reduced proliferation rate/quiescence, adaptation to hostile conditions such as inflammation and low nutrient availability, metabolic reprogramming, marked resistance to oxidative stress, the ability to rapidly activate detoxifying strategies by ATP-binding cassette transporters, enhanced and quick DNA damage responses, and impaired apoptotic machinery. 
| Epithelial-mesenchymal transition (EMT) and CSCs
Epithelial-mesenchymal transition is a latent embryonic program implicated in cancer invasion and metastasis. 36 In EMT, epithelial cancer cells lose their adhesive properties and acquire a mesenchymal trait. Epithelial-mesenchymal transition is a complex process that involves many transcription factors including, but not limited to, SNAIL, SLUG, TWIST, ZEB1, SIP1, and E47. Many pathways play crucial roles in EMT such as Wnt, Notch, nuclear factor-κB, Hedgehog, and transforming growth factor-β (TGF-β). 37 Cells undergoing EMT can acquire stem cell-like features to become CSCs. 38 The tumor microenvironment also plays a crucial role in exerting selective pressure during the development of CSCs with metastatic properties, a process attributed to multiple cytokines participating in the various pathways mentioned above and derived from the surrounding stroma and stromal cells including tumor-associated macrophages and cancer-associated fibroblasts. 35 
| Effect of PARPi on CSCs
The role of PARPi on CSCs is unknown; however, there is indirect evidence to suggest CSCs are resistant to PARPi. Yamaguchi et al 39 reported that inhibition of PARP1 with olaparib activated EZH2 and increased the formation of breast cancer CSCs. In another study of human TNBC cell lines, even though tumor bulk reduced when treated with a PARPi, there was CSC sparing. 40 Various other features of CSCs are described that confer resistance to standard therapeutics (Table 4) . Poly (ADP-ribose) polymerase inhibitors share many of these mechanisms, and it is reasonable to presume that PARPi are very unlikely to exert significant cytotoxicity on CSCs (Figure 1 ).
| Effect of PD-1/PD-L1 inhibitors on CSCs
The direct impact of immunotherapy on the CSC population is currently unknown; however, it is unlikely to have a significant impact on its own based on current evidence. 
TA B L E 4 Potential pathways and therapeutic strategies against cancer stem cells (CSCs)
correlation between the stemness score of the breast cancer and PD-L1 levels. 43 Furthermore, PD-L1 knockdown decreased expression of embryonic stem cell transcription factors like octamerbinding transcription factor-4A, Nanog, and the stemness factor BMI1. Wnt signaling might also be associated with PD1i resistance, and Wnt is a crucial pathway in EMT and CSC formation. 44 
| EPI G ENE TI C S
Epigenetics is defined as heritable modifications to DNA without alteration in the nucleotide sequence, resulting in altered gene transcription and chromatin structure. 45 
| Lysine-specific histone demethylase-1A (LSD1) and LSD1 inhibitors
Lysine-specific histone demethylase-1A specifically demethylates mono-or dimethylated histone3 lysine4 (H3K4) or histone3 lysine9 (H3K9). Lysine-specific histone demethylase-1A is required for normal stem cell differentiation and maintenance. It is overexpressed in some cancers including bladder, prostate, and lung cancers. 46 LSD1 knockdown reduces LSD1 expression and inhibits cancer growth, migration, and invasion. In breast cancer, LSD1 expression increases when ductal carcinoma in situ progresses to invasive ductal carcinoma. 47 In addition, LSD1 is overexpressed in TNBCs, and their stemness properties proportionately increase with LSD1 expression. 48 High LSD1 levels are seen during EMT in MCF-7 breast cancer cells following stimulation with Phorbol 12-myristate-13-acetate/TGF-β and in fully dedifferentiated mesenchymal MDA-MB-231 breast cancer cells.
Decreased LSD1 levels have also been reported during the opposing biological process, mesenchymal-epithelial transition. 49 Boulding et al 49 
| Histone deacetylase and HDACi
Histone deacetylase is a family of hydrolases that remove acetyl groups from lysine residues on histones, and they play important and varied roles in tumorigenesis, including regulation of numerous genes responsible for tumor initiation and progression, angiogenesis, and cell migration. 50 54 an effect thought to be related to downregulation of the transcription factor E2F1.
Further supporting this, PCI-24781, an HDACi, decreased RAD51
and HR pathway expression. 55 In this background, many epigenetic drugs have been combined with PARPi in the hope of enhancing DNA damage and inducing BRCAness. 
| FINAL D ISCUSS I ON AND FUTURE S TR ATEG IE S
The combination of PARPi with a PD-1 or PD-L1 inhibitor has a very promising biological rationale for synergy; however, as discussed above, both drugs are unlikely to have a significant impact on CSCs.
This could lead to residual tumors enriched with CSCs that might eventually relapse, progress, and metastasize despite initial tumor shrinkage. Hence, it is of the utmost importance that future therapeutic strategies should incorporate drugs targeting CSCs. inhibition of Notch has also been shown to cause compensatory activation of Hedgehog signaling in the skin. 66 Hedgehog signaling was found to inhibit Wnt signaling through upregulation of secreted frizzled-related protein 1, so inhibition of the Hedgehog pathway could potentially activate Wnt signaling. 67 We, therefore, believe that combination strategies targeting multiple signals in the same cascade are less likely to provide an acceptable clinical yield, especially with respect to long-term survival, due to the numerous genes, signaling pathways, and effector proteins involved. The effect of epigenetic drugs on CSCs is an upstream effect that is likely to have controlled inhibition/regulation of all corresponding downstream cascades.
Although toxicity is always a concern with combination therapy, as seen in PARPi/chemotherapy trials, it is possible that low doses of epigenetic drugs could be adequate to induce durable responses, hence the risk of added toxicity is expected to be lower when used in this way. 59 In addition, the rate of serious toxicity is low with PD1i and the spectrum of toxicity is distinct to the other two drug classes.
We propose the addition of epigenetic drugs to a PARPi/PD1i combination might be synergistic and could potentially overcome different resistance mechanisms, causing cytotoxic cell death by DNA damage, suppression of CSCs, and potentiating immunogenic cell death (Figure 2) . 
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